传统新药研发平均耗时10-15年，花费超过20亿美元，而失败率高达95%。其根本原因在于，我们一直未能精准分析药物、靶点与机体之间的三重相互作用。面对这一困境，李翛然讲述了自己团队将AI技术与量子计算相结合，构建了“Quantum AIDD”（量子计算+AI药物设计）平台，通过高效求解薛定谔方程，提升药物分子模拟的精度和速度，推动定制化药物设计的故事。 李翛然博⼠是量子计算与AI制药领域的创新先锋，医图⽣科创始⼈兼CEO，CCF会员。他在量子计算和药物研发领域深耕，发表多篇SCI论⽂，拥有数项药物发明全球专利。作为业内先行者；主导医图⽣科的研发与商业化，开展了AI与量子计算在⽣物医药中的研究及应⽤项⽬。他将量子计算融⼊药物设计流程，探索未曾被AI与人类观察到的生物现象，开启“量⼦AI药物设计”时代，为制药⾏业带来全新的变革路径。 This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at https://ww ...

Group 1 - Shanghai has issued measures to promote high-quality development in the pharmaceutical industry, including reducing the clinical trial review and approval time for innovative drugs to 30 working days [1] - The integration of China's drug review technical requirements with international standards allows for more participation in the formulation and implementation of global rules, enabling simultaneous application for new drug listings in China and abroad [1] - Companies with strong financial capabilities and rich R&D pipelines are expected to benefit significantly from the optimized review and approval processes [1] Group 2 - The innovative drug sector is anticipated to perform well in terms of revenue and profit, driven by accelerated new drug listings and ongoing business development (BD) transactions [1] - National Investment Securities predicts multiple overseas licensing BD transactions for domestic innovative drugs in the fourth quarter of 2025, indicating a promising outlook for the innovative drug market [2] Group 3 - Hongbo Pharmaceutical, a local Shanghai company, operates in small molecule innovative drug CRO, CDMO, CMO, and commercial production, and has developed an AI drug design platform [3] - Shanghai Yizhong focuses on the R&D, production, and sales of anti-tumor innovative drugs, with its main product being injectable paclitaxel polymer micelles [3]

Core Viewpoint - Li Ka-shing's recent decision to sell 400 properties during a downturn in the real estate market has raised questions about his confidence in the Chinese market and the underlying reasons for this move [1][5]. Group 1: Historical Context and Market Changes - Li Ka-shing has historically been known for his strategic timing in the real estate market, buying during lows and selling during highs [1]. - His previous strategy involved long-term land holding and gradual development, which has become increasingly difficult due to intensified government measures against idle land [3][5]. - The current real estate market in China is undergoing a deep adjustment, making the previous "time for space" strategy a liability rather than an asset [5][7]. Group 2: Shift in Investment Focus - Li Ka-shing's recent actions reflect a broader shift among capital players towards sectors with more stable returns, such as energy, infrastructure, and emerging technologies like AI and life sciences [5][7]. - The global trend indicates a decline in returns from hard assets, while sectors driven by technological innovation, particularly AI and biotechnology, are opening new wealth opportunities [7][8]. - The demand for healthspan extension is a global consensus, with AI accelerating advancements in drug design and gene editing, making these sectors attractive for investment [8][10]. Group 3: Strategic Implications - The shift from real estate to technology and life sciences is not merely a reaction but a strategic decision to mitigate risks and enhance asset security [5][12]. - Li Ka-shing's transition signifies a move from low-efficiency, high-risk sectors to more certain and globally relevant industries, aligning with the need for dynamic asset allocation in an uncertain global environment [13][15]. - The decision to divest from real estate can be seen as a calculated move to position for future growth opportunities, emphasizing the importance of adapting to market changes [17].

Core Viewpoint - The company has established a systematic layout in AI drug design, focusing on computing power, data resources, and vertical large models [1] Group 1 - The company possesses stable and efficient computing resources that support key tasks such as drug design, molecular simulation, and model training [1] - The company has accumulated rich data resources and built a knowledge graph, providing solid support for large models [1] - The company has independently developed a vertical large model in the biopharmaceutical field, covering functions such as literature research, drug design and evaluation, and patent infringement analysis, while continuously enhancing its intelligence capabilities [1]

Core Viewpoint - The article discusses the rapid development and potential of the biomanufacturing industry, highlighting its role in the Fourth Industrial Revolution and the significant growth opportunities it presents in various sectors, particularly in China [3][4]. Industry Overview - Biomanufacturing is defined as an advanced production method centered on industrial biotechnology, utilizing biological resources and processes to produce target products at scale [5]. - The global biomanufacturing industry is projected to reach approximately $12,190 billion in 2024, with a year-on-year growth of 7.4%, and is expected to exceed $20 trillion by 2030, with a compound annual growth rate (CAGR) of 8.4% [9]. Market Dynamics - In China, the biomanufacturing industry is anticipated to reach a scale of 1.01 trillion yuan in 2024, growing by 15.4%, and is expected to surpass 2.5 trillion yuan by 2030, with a CAGR of 16.8% [9][10]. - The top three segments in China's biomanufacturing industry in 2024 will be biopharmaceuticals, biological food, and bio-chemical products, with biopharmaceuticals remaining the largest segment [10]. Technological Advancements - The industry is experiencing a shift from traditional resource reliance to technology-driven approaches, with significant improvements in biomass resource utilization and equipment efficiency [8]. - Innovations in biopharmaceuticals, such as the development of bispecific antibodies and ADC drugs, have seen an annual growth of 65% in product pipelines [8][12]. Application and Impact - In the medical field, biomanufacturing technologies like 3D printing are enabling personalized implants, achieving gross margins of 75% [9]. - In agriculture, microbial fertilizers have improved corn yields by 12% while reducing chemical fertilizer usage by 30% [9]. Future Trends - The article outlines several key trends, including the restructuring of industrial ecosystems, regional layout changes, deepening technological revolutions, product innovation iterations, and capital factor restructuring [17][18][19]. - The integration of AI and biotechnology is expected to enhance production efficiency and product quality, with significant implications for the industry [18]. Strategic Recommendations - Companies are encouraged to build a three-dimensional competitive system focusing on technology research and development, scene innovation, and ecosystem construction [20]. - Local governments should create a supportive industrial service matrix to foster the growth of the biomanufacturing sector [20].

Core Viewpoint - The company reported a significant decline in revenue and an increase in net loss for Q1 2025, primarily due to the absence of licensing income and high R&D expenses, despite some progress in its pipeline [1][2][4]. Revenue Summary - Total revenue for Q1 2025 was 44.79 million yuan, a year-on-year decrease of 33.7% - Drug sales revenue reached 44.72 million yuan, showing a growth of 149.77%, but overall revenue decline was attributed to no licensing income this quarter, unlike the previous year when income was recognized from a licensing agreement with DISC MEDICINE [1]. Profit Summary - The net loss attributable to shareholders was 292 million yuan, an increase of 86.07 million yuan compared to the same period last year - High R&D expenses amounted to 209 million yuan, a year-on-year increase of 14.5%, representing 465.62% of total revenue, which was used to advance 16 core pipeline projects [1]. Pipeline Progress - The company made significant advancements in its pipeline, presenting six innovative products and platform research results at the AACR conference - NECTIN-4 ADC was included in the list of breakthrough therapies by the National Medical Products Administration in January 2025 - The monoclonal antibody 9MW1911 completed its clinical trial enrollment for COPD patients and is expected to finish follow-ups in the second half of 2025 - The monoclonal antibody 9MW3011 also completed its first patient enrollment in January 2025 - A collaboration with Insilico Medicine was established to optimize drug design processes using AI algorithms [2][3]. Research Outcomes - At the AACR annual meeting, the company showcased six innovative products and platform research results - ADC candidates demonstrated promising anti-tumor effects, including B7-H3 ADC in combination with PARP inhibitors and a new CLDN1-targeting ADC showing significant efficacy in preclinical studies - The dual antibody platform showed strong anti-tumor activity in preclinical models for acute myeloid leukemia [3]. Profit Forecast - Revenue projections for 2025-2027 are 851 million, 1.514 billion, and 2.08 billion yuan, with year-on-year growth rates of 325.97%, 77.91%, and 37.38% respectively - Net profit attributable to shareholders is forecasted to be -591 million, -280 million, and 104 million yuan, with year-on-year growth rates of 43.4%, 52.65%, and 137.14% respectively [4].